During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of ...

弥漫大 B 细胞淋巴瘤（DLBCL）患者预后差异大，机制不明。研究人员开展 BEND4 对 DLBCL 预后影响的研究，发现高表达 BEND4 与患者不良预后、化疗耐药相关，BEND4 或可作诊疗靶点，为 DLBCL 治疗带来新方向。

A next-generation, anti-CD19 enhanced (or "armored") CAR T-cell product showed promising efficacy and safety in a phase I ...

弥漫大 B 细胞淋巴瘤（DLBCL）治疗面临挑战，研究人员探究过氧化物还原酶 1（PRDX1）对 DLBCL 铁死亡的作用及机制。发现 PRDX1 敲低可促进铁死亡、抑制 DLBCL 发展，为 DLBCL 治疗提供新策略。

Dr. Kara Kelly discusses the unique challenges that adolescent and young adult patients with cancer face following their ...

A patient with heavily pretreated relapsed/refractory diffuse large B-cell lymphoma achieved complete remission following ...

During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell ...

编者按：2025年美国临床肿瘤学会年会（ASCO）将于美国东部时间（GMT-5）5月30日至6月3日在芝加哥召开。作为全球规模最大、学术水平最高、最具权威性的国际肿瘤会议之一，2025年ASCO年会将汇聚顶级肿瘤专家、学者和行业领袖，共探肿瘤领域的前沿研究成果和先进治疗方法。

The Seoul Hospital (Hospital Director Lee Jung-jae) affiliated with Soonchunhyang University recently started CAR-T cell ...